doxecitine and doxribtimine
doxecitine and doxribtimine is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including KYGEVVI. Available dosage form: powder, for solution.
Drug Details
- Generic Name
- doxecitine and doxribtimine
- Brand Names
- KYGEVVI
- Application Number
- NDA219792
- Sponsor
- UCB, Inc.
- NDC Codes
- 1
- Dosage Forms
- POWDER, FOR SOLUTION
- Routes
- ORAL
- Active Ingredients
- DOXECITINE, DOXRIBTIMINE
Indications and Usage
1 INDICATIONS AND USAGE KYGEVVI is indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years. KYGEVVI is a combination of doxecitine and doxribtimine, both pyrimidine nucleosides, indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years. ( 1 )